Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy

[1] Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[2] Miller KD(2001)Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655-1659

[3] Jemal A(2001)Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966-970

[4] Flanigan RC(2004)Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 1071-1076

[5] Salmon SE(2011)The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 60-66

[6] Blumenstein BA(2014)Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium Eur Urol 66 704-710

[7] Mickisch GH(2015)Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features Urol Oncol 33 339.e9-339.15

[8] Garin A(2014)Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study Clin Genitourin Cancer 12 373-383

[9] Van PH(2015)Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis Int Braz J Urol 41 288-295

[10] Flanigan RC(2014)Tsivian M et al.Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era Anticancer Res 34 2405-2411

[1] Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[2] Miller KD(2001)Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer N Engl J Med 345 1655-1659

[3] Jemal A(2001)Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial Lancet 358 966-970

[4] Flanigan RC(2004)Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis J Urol 171 1071-1076

[5] Salmon SE(2011)The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy J Urol 185 60-66

[6] Blumenstein BA(2014)Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the international metastatic renal cell carcinoma database consortium Eur Urol 66 704-710

[7] Mickisch GH(2015)Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features Urol Oncol 33 339.e9-339.15

[8] Garin A(2014)Prognostic significance of cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma treated with first-line sunitinib: a European multiinstitutional study Clin Genitourin Cancer 12 373-383

[9] Van PH(2015)Assessment of survival of patients with metastatic clear cell renal cell carcinoma after radical cytoreductive nephrectomy versus no surgery: a seer analysis Int Braz J Urol 41 288-295

[10] Flanigan RC(2014)Tsivian M et al.Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era Anticancer Res 34 2405-2411